Medication Reconciliation & More...Topics for Patient Safety

Interprofessional Clinical Management: Diabetes

Activity Details
  • Credit Amounts:
    • CNE: 0.60
    • CPH: 0.50
    • TSBSWE: 0.50
    • Physicians: 0.50
    • PT: 0.50
    • IACET: 0.50
  • Cost: Free
  • Release: Dec 15, 2016
  • Expires: Dec 15, 2017
  • Estimated Time to Complete:
    30 Minutes
  • System Requirements:
  • Average User Rating:
    ( Ratings)

Faculty

Emily Knezevich Emily Knezevich, PharmD
Associate Professor
School of Pharmacy & Health Professions
Creighton University

Needs Statement

9.3% of the US population has been estimated to have diabetes, with approximately 28% of those individuals being undiagnosed. The rate of diabetes prevalence has increased at an alarming rate over the last 50 years and the changing prevalence of obesity and diabetes is clearly a national epidemic affecting every region in the US.  This activity will guide practitioners through the need to address diabetes in a team-based and patient-centered approach.

 

 

 

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, nurse practitioners, nurses that care for patients with diabetes.

Objectives

  1. Define pathophysiologic defects resulting in diabetes and review current prevalence of diabetes in the US and its resultant economic burden.
  2. Compare pharmacotherapeutic options for treating diabetes, emphasizing recommendations for and against use in individual patient.
  3. Discuss major components of diabetes self-management education.
  4. Review the benefits of the patient centered medical home in managing patients with diabetes.

Accreditation

CNE

UNT Health Science Center is approved by the California Board of Registered Nursing, Provider # 16274. This activity is approved for 0.60 Contact Hours.

CPH

This activity is approved for 0.50 credit(s) accepted by the National Board of Public Health Examiners' Certified Public Health (CPH) recertification program.

TSBSWE

This activity is approved for a maximum of 0.50 Clock Hours for Social Workers.

Physicians

The University of North Texas Health Science Center is accredited by the American Osteopathic Association to award continuing medical education to physicians.

The University of North Texas Health Science Center has requested that the AOA Council on Continuing Medical Education approve this program for 0.50 hour of AOA Category 2A CME credits. Approval is currently pending.

The University of North Texas Health Science Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of North Texas Health Science Center designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of North Texas Health Science Center presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

ACGME Competencies

  • Patient care
  • Medical knowledge

PT

UNT Health Science Center is accredited by Texas Physical Therapy Association, Provider 1810035TX. This activity is approved for 0.50 CCUs for PTs and PTAs.

For successful completion, a participant must attend the program, complete the evaluation, and request credit online at conclusion of the activity.

The assignment of Texas PT CCUs does not imply endorsement of specific course content, products, or clinical procedures by TPTA or TBPTE.

IACET
The University of North Texas Health Science Center is accredited by the International Association for Continuing Education and Training (IACET) to apply 0.50 contact hours (0.05 CEUs) to participants.

Faculty Disclosure

The faculty will discuss GLP-1 agonists use in combination with basal insulin and not all GLP-1 agonists are currently FDAapproved for use with both available forms of basal insulin.

Otherwise, the faculty has no conflict of interests to disclose.